Leerink Partnrs Has Pessimistic Outlook of CRNX Q3 Earnings

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) – Equities researchers at Leerink Partnrs cut their Q3 2025 earnings estimates for Crinetics Pharmaceuticals in a research note issued to investors on Tuesday, February 4th. Leerink Partnrs analyst J. Schwartz now expects that the company will earn ($1.14) per share for the quarter, down from their previous estimate of ($1.12). The consensus estimate for Crinetics Pharmaceuticals’ current full-year earnings is ($3.73) per share. Leerink Partnrs also issued estimates for Crinetics Pharmaceuticals’ Q4 2025 earnings at ($1.22) EPS, FY2025 earnings at ($4.24) EPS and FY2026 earnings at ($4.99) EPS.

CRNX has been the subject of a number of other reports. Wolfe Research initiated coverage on Crinetics Pharmaceuticals in a report on Tuesday. They issued a “peer perform” rating for the company. Citigroup increased their price target on shares of Crinetics Pharmaceuticals from $70.00 to $74.00 and gave the company a “buy” rating in a research report on Thursday, November 14th. JMP Securities restated a “market outperform” rating and issued a $87.00 price objective on shares of Crinetics Pharmaceuticals in a report on Monday, December 16th. Jefferies Financial Group raised shares of Crinetics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a research note on Wednesday, January 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $81.00 target price on shares of Crinetics Pharmaceuticals in a research report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, Crinetics Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $72.64.

Crinetics Pharmaceuticals Stock Performance

Shares of NASDAQ:CRNX opened at $36.98 on Friday. The firm has a fifty day moving average of $47.81 and a 200 day moving average of $51.89. Crinetics Pharmaceuticals has a 52-week low of $35.51 and a 52-week high of $62.53. The firm has a market capitalization of $3.43 billion, a PE ratio of -9.91 and a beta of 0.56.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.05). During the same period in the previous year, the company earned ($1.01) EPS.

Insider Transactions at Crinetics Pharmaceuticals

In other Crinetics Pharmaceuticals news, COO Jeff E. Knight sold 501 shares of the company’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $56.52, for a total value of $28,316.52. Following the completion of the transaction, the chief operating officer now directly owns 51,653 shares in the company, valued at approximately $2,919,427.56. This represents a 0.96 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Dana Pizzuti sold 5,000 shares of Crinetics Pharmaceuticals stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $39.07, for a total transaction of $195,350.00. Following the sale, the insider now directly owns 31,748 shares in the company, valued at $1,240,394.36. The trade was a 13.61 % decrease in their position. The disclosure for this sale can be found here. 6.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Crinetics Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Venturi Wealth Management LLC purchased a new position in shares of Crinetics Pharmaceuticals during the 4th quarter worth approximately $41,000. Values First Advisors Inc. bought a new stake in shares of Crinetics Pharmaceuticals during the third quarter valued at approximately $84,000. Allspring Global Investments Holdings LLC purchased a new stake in Crinetics Pharmaceuticals in the third quarter worth $91,000. KBC Group NV raised its holdings in Crinetics Pharmaceuticals by 22.8% in the third quarter. KBC Group NV now owns 2,193 shares of the company’s stock worth $112,000 after purchasing an additional 407 shares in the last quarter. Finally, Advisors Asset Management Inc. raised its holdings in Crinetics Pharmaceuticals by 56.1% in the third quarter. Advisors Asset Management Inc. now owns 2,806 shares of the company’s stock worth $143,000 after purchasing an additional 1,008 shares in the last quarter. 98.51% of the stock is owned by institutional investors.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.